MedTrace Logo

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

NCT02982915 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-11-04

No results posted yet for this study

Summary

This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.

Conditions

  • Aging Frailty

Interventions

BIOLOGICAL

Longeveron Mesenchymal Stem Cells (LMSCs)

Intravenously delivered

BIOLOGICAL

Fluzone High Dose Vaccine

Intramuscular injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-09-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02982915 on ClinicalTrials.gov